You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

~ Buy the APRETUDE (cabotegravir) Drug Profile, 2024 PDF Report in the Report Store ~

APRETUDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Apretude, and when can generic versions of Apretude launch?

Apretude is a drug marketed by Viiv Hlthcare and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and fifty-seven patent family members in thirty-eight countries.

The generic ingredient in APRETUDE is cabotegravir. One supplier is listed for this compound. Additional details are available on the cabotegravir profile page.

DrugPatentWatch® Generic Entry Outlook for Apretude

Apretude will be eligible for patent challenges on January 21, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 15, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for APRETUDE?
  • What are the global sales for APRETUDE?
  • What is Average Wholesale Price for APRETUDE?
Summary for APRETUDE
International Patents:157
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 53
Clinical Trials: 4
Patent Applications: 322
Drug Prices: Drug price information for APRETUDE
What excipients (inactive ingredients) are in APRETUDE?APRETUDE excipients list
DailyMed Link:APRETUDE at DailyMed
Drug patent expirations by year for APRETUDE
Drug Prices for APRETUDE

See drug prices for APRETUDE

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for APRETUDE
Generic Entry Date for APRETUDE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for APRETUDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
GlaxoSmithKlinePhase 3
ViiV HealthcarePhase 3
PPDPhase 3

See all APRETUDE clinical trials

US Patents and Regulatory Information for APRETUDE

APRETUDE is protected by three US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of APRETUDE is ⤷  Subscribe.

This potential generic entry date is based on patent 11,224,597.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare APRETUDE cabotegravir SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 215499-001 Dec 20, 2021 RX Yes Yes 10,927,129 ⤷  Subscribe Y Y ⤷  Subscribe
Viiv Hlthcare APRETUDE cabotegravir SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 215499-001 Dec 20, 2021 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Viiv Hlthcare APRETUDE cabotegravir SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 215499-001 Dec 20, 2021 RX Yes Yes 8,410,103 ⤷  Subscribe Y Y ⤷  Subscribe
Viiv Hlthcare APRETUDE cabotegravir SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 215499-001 Dec 20, 2021 RX Yes Yes 11,224,597 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for APRETUDE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
ViiV Healthcare B.V. Vocabria cabotegravir EMEA/H/C/004976
Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA
Authorised no no no 2020-12-17
ViiV Healthcare B.V. Apretude cabotegravir EMEA/H/C/005756
Apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4.2, 4.4 and 5.1).
Authorised no no no 2023-09-15
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for APRETUDE

When does loss-of-exclusivity occur for APRETUDE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 11302030
Patent: Pharmaceutical compositions
Estimated Expiration: ⤷  Subscribe

Brazil

Patent: 2013005907
Patent: composição farmacêutica parenteral, métodos para o tratamento e para prevenção de uma infecção por hiv, e, uso de uma composição farmacêutica
Estimated Expiration: ⤷  Subscribe

Canada

Patent: 10524
Patent: COMPOSITIONS PHARMACEUTIQUES (PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷  Subscribe

Chile

Patent: 13000715
Patent: Composicion farmaceutica que comprende (3s,11ar)-n-[(2,4-difluorofenil)metil]-2,3,5,7,11,11a-hexahidro-6-hidroxi-3-metil-5,7-dioxo-oxazolo[3,2-a]pirido[1,2-d]pirazin-8-carboxamida y un sistema de agente tensoactivo de polisorbato y polietilenglicol; metodo de tratamiento; y su uso para tratar o prevenir una infeccion por vih.
Estimated Expiration: ⤷  Subscribe

China

Patent: 3547266
Patent: Pharmaceutical compositions
Estimated Expiration: ⤷  Subscribe

Croatia

Patent: 0161280
Estimated Expiration: ⤷  Subscribe

Cyprus

Patent: 18279
Estimated Expiration: ⤷  Subscribe

Denmark

Patent: 16076
Estimated Expiration: ⤷  Subscribe

Eurasian Patent Organization

Patent: 4924
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ (PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷  Subscribe

Patent: 1390233
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
Estimated Expiration: ⤷  Subscribe

European Patent Office

Patent: 16076
Patent: COMPOSITIONS PHARMACEUTIQUES (PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷  Subscribe

Hungary

Patent: 31336
Estimated Expiration: ⤷  Subscribe

Israel

Patent: 5028
Patent: תכשיר רוקחי פרנטרלי לשימוש בטיפול בזיהום על ידי hiv באדם (Parenteral pharmaceutical composition for use in the treatment of an hiv infection in a human)
Estimated Expiration: ⤷  Subscribe

Japan

Patent: 31385
Estimated Expiration: ⤷  Subscribe

Patent: 14500849
Estimated Expiration: ⤷  Subscribe

Lithuania

Patent: 16076
Estimated Expiration: ⤷  Subscribe

Mexico

Patent: 6193
Patent: COMPOSICIONES FARMACEUTICAS. (PHARMACEUTICAL COMPOSITIONS.)
Estimated Expiration: ⤷  Subscribe

Patent: 13003037
Patent: COMPOSICIONES FARMACEUTICAS. (PHARMACEUTICAL COMPOSITIONS.)
Estimated Expiration: ⤷  Subscribe

Montenegro

Patent: 520
Patent: FARMACEUTSKE KOMPOZICIJE (PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷  Subscribe

Poland

Patent: 16076
Estimated Expiration: ⤷  Subscribe

Portugal

Patent: 16076
Estimated Expiration: ⤷  Subscribe

San Marino

Patent: 01600350
Patent: COMPOSIZIONI FARMACEUTICHE
Estimated Expiration: ⤷  Subscribe

Serbia

Patent: 222
Patent: FARMACEUTSKE KOMPOZICIJE (PHARMACEUTICAL COMPOSITIONS)
Estimated Expiration: ⤷  Subscribe

Slovenia

Patent: 16076
Estimated Expiration: ⤷  Subscribe

South Africa

Patent: 1301766
Patent: PHARMACEUTICAL COMPOSITIONS
Estimated Expiration: ⤷  Subscribe

South Korea

Patent: 1938662
Estimated Expiration: ⤷  Subscribe

Patent: 130116254
Patent: PHARMACEUTICAL COMPOSITIONS
Estimated Expiration: ⤷  Subscribe

Spain

Patent: 94557
Estimated Expiration: ⤷  Subscribe

Taiwan

Patent: 77377
Estimated Expiration: ⤷  Subscribe

Patent: 1223529
Patent: Pharmaceutical compositions
Estimated Expiration: ⤷  Subscribe

Ukraine

Patent: 8250
Patent: ПАРЕНТЕРАЛЬНА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЇЇ ЗАСТОСУВАННЯ ТА СПОСОБИ ЛІКУВАННЯ АБО ПОПЕРЕДЖЕННЯ ВІЛ-ІНФЕКЦІЇ У ЛЮДИНИ
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering APRETUDE around the world.

Country Patent Number Title Estimated Expiration
Japan 5131689 ⤷  Subscribe
South Korea 20080064182 POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE ⤷  Subscribe
Brazil PI0610030 composto, processo para a preparação de um composto, método de tratamento de uma infecção por hiv em um humano, uso de um composto, e, composição farmacêutica ⤷  Subscribe
Israel 225028 תכשיר רוקחי פרנטרלי לשימוש בטיפול בזיהום על ידי hiv באדם (Parenteral pharmaceutical composition for use in the treatment of an hiv infection in a human) ⤷  Subscribe
Slovenia 3045206 ⤷  Subscribe
Morocco 29460 DERIVE POLYCYCLIQUE DE LA CARBAMOYLPYRIDONE A ACTIVITE INHIBITRICE SUR L'INTEGRASE DU VIH ⤷  Subscribe
China 101212903 Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for APRETUDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1874117 14C0041 France ⤷  Subscribe PRODUCT NAME: DOLUTEGRAVIR ET SES SELS OU SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES,NOTAMMENT LE DOLUTEGRAVIR SODIQUE.; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
1874117 300676 Netherlands ⤷  Subscribe PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, MET INBEGRIP VAN DOLUTEGRAVIR NATRIUM; REGISTRATION NO/DATE: EU/1/13/892 20140121
2465580 122021000021 Germany ⤷  Subscribe PRODUCT NAME: CABOTEGRAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/20/1481 20201217
2465580 CR 2021 00010 Denmark ⤷  Subscribe PRODUCT NAME: CABOTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/20/1481 20201221
1874117 122014000066 Germany ⤷  Subscribe PRODUCT NAME: DOLUTEGRAVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SOLVAT DAVON, EINSCHLIESSLICH DOLUTEGRAVIRNATRIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140116
2465580 C 2021 017 Romania ⤷  Subscribe PRODUCT NAME: CABOTEGRAVIR; NATIONAL AUTHORISATION NUMBER: EU/1/20/1481; DATE OF NATIONAL AUTHORISATION: 20201217; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1481; DATE OF FIRST AUTHORISATION IN EEA: 20201217
2465580 PA2021512,C2465580 Lithuania ⤷  Subscribe PRODUCT NAME: KABOTEGRAVIRAS; REGISTRATION NO/DATE: EU/1/20/1481 20201217
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

APRETUDE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Apretude

Introduction to Apretude

Apretude, also known as cabotegravir, is a groundbreaking long-acting injectable drug developed by ViiV Healthcare, a subsidiary of GlaxoSmithKline (GSK), for the prevention of HIV infection. This drug has revolutionized the HIV pre-exposure prophylaxis (PrEP) market by offering an alternative to daily oral medications.

Market Position and Competition

Apretude has entered a market dominated by Gilead Sciences’ oral PrEP drugs, such as Truvada and its generic versions. However, Apretude's unique selling point is its long-acting injectable formulation, which is administered every eight weeks. This has shown significant efficacy in reducing the risk of HIV infection, with a 69% reduction in men and transgender women and an 89% reduction in women compared to Truvada[2].

Sales Performance and Growth Projections

Since its FDA approval in December 2021, Apretude has demonstrated robust sales growth. In the second quarter of 2022, Apretude generated £8 million in sales, while its counterpart, Cabenuva, a long-acting treatment for HIV, registered £72 million in sales[2].

GSK has revised its medium-term growth forecast for its HIV drug business, driven largely by the success of Apretude. The company now projects annual sales growth rates of 6% to 8% from 2021 to 2026, aiming for sales between £6 billion and £7 billion by 2026[4].

Market Share and Expansion

ViiV Healthcare holds a significant market share in the HIV treatment and prevention market. In the US, ViiV has about 25.5% of the market share, with Apretude and Cabenuva contributing substantially to this figure. The overall HIV market is valued at USD 28 billion, with a growing number of infected individuals each year[1].

Apretude is expected to play a crucial role in expanding ViiV’s market share, particularly as it gains broader reimbursement in the United States and Europe. The drug’s acceptance is driven by its convenience and efficacy, addressing the challenges of adherence associated with daily oral PrEP medications[4].

Global Access and Licensing

To enhance global access to Apretude, GSK has signed a licensing deal with the Medicines Patent Pool (MPP), allowing selected generics manufacturers to produce and supply the drug in 90 poorer countries. This initiative aims to make the drug more accessible in regions with the highest burden of HIV, such as sub-Saharan Africa[2].

Financial Outlook and Revenue Projections

The financial trajectory for Apretude is promising. ViiV Healthcare anticipates that its long-acting portfolio, including Apretude, will deliver over £2 billion in sales by 2026, representing about one-third of the company’s overall HIV sales during this period[3].

Apretude’s list price is approximately $3,700 per vial, or $22,200 per year. However, generics manufacturers could potentially produce the drug at a significantly lower cost, around $2.60 per vial, according to research by the Clinton Health Access Initiative[2].

Future Developments and Dosing Intervals

GSK is committed to further enhancing the convenience of Apretude. The company plans to extend the dosing interval to every four months by 2026 and aims to achieve a six-month dosing interval by the end of the decade. Additionally, there are plans to develop self-administered formulations, which could significantly improve patient compliance and convenience[1][3].

Patent Expiry and Long-Term Prospects

While the core patent for dolutegravir, ViiV’s top-selling anti-HIV drug, is set to expire in 2028, the patents for Apretude and other long-acting formulations are expected to remain valid until 2031 or beyond. This extended period of exclusivity is crucial for maintaining ViiV’s market leadership and ensuring continued revenue growth[3].

Challenges and Implementation

Despite its potential, Apretude faces several challenges, including logistical issues in low-income regions where healthcare infrastructure may not be as robust. Doctors prescribing HIV medications are also in the process of adapting to the administration of injectable drugs, which requires additional training and infrastructure setup[2].

Key Trends Shaping the Market

The HIV treatment and prevention market is influenced by several key trends, including the persistence of stigma and inequity, low PrEP utilization rates, and increasing payer pressure. However, the strong demand for long-acting injectables and the focus on access and equity are driving market dynamism[3].

Community Engagement and Access

ViiV Healthcare and its partners are actively engaged in ensuring equitable access to Apretude. Collaborations with organizations like the Bill & Melinda Gates Foundation, the Children’s Investment Fund Foundation, and Unitaid are facilitating pricing discussions for government purchases and implementing studies to optimize drug delivery in different settings[2].

Conclusion

Apretude has emerged as a game-changer in the HIV PrEP market, offering a convenient and highly effective alternative to daily oral medications. With strong sales growth, expanded global access initiatives, and a robust financial outlook, Apretude is poised to continue driving ViiV Healthcare’s leadership in the HIV treatment and prevention market.

Key Takeaways

  • Apretude is a long-acting injectable PrEP drug that has shown significant efficacy in reducing HIV infection risk.
  • The drug has gained strong market acceptance, contributing to ViiV Healthcare’s revised growth forecasts.
  • Global access initiatives, including a licensing deal with the Medicines Patent Pool, aim to make Apretude available in poorer countries.
  • Future developments include extended dosing intervals and self-administered formulations.
  • Patent exclusivity for Apretude is expected to last until 2031 or beyond.

Frequently Asked Questions

What is Apretude and how does it work?

Apretude, or cabotegravir, is a long-acting injectable drug used for HIV pre-exposure prophylaxis (PrEP). It is administered every eight weeks and has shown to significantly reduce the risk of HIV infection compared to daily oral PrEP medications.

How effective is Apretude in preventing HIV?

Apretude has been shown to reduce the risk of HIV infection by 69% in men and transgender women and by 89% in women compared to Truvada[2].

What are the challenges in implementing Apretude in low-income regions?

Implementing Apretude in low-income regions faces logistical challenges, including the need for healthcare infrastructure to administer the injections and the higher cost compared to generic oral PrEP medications[2].

How does Apretude’s pricing compare to other PrEP options?

Apretude’s list price is approximately $3,700 per vial, or $22,200 per year. However, generics manufacturers could produce it at a lower cost, around $2.60 per vial[2].

What are the future plans for Apretude’s dosing intervals?

GSK plans to extend the dosing interval for Apretude to every four months by 2026 and aims to achieve a six-month dosing interval by the end of the decade[1][3].

Cited Sources:

  1. SHIONOGI & CO., LTD. - SHIONOGI & CO., LTD. Investor Presentation.
  2. FiercePharma - GSK feeds HIV PrEP drug to Medicines Patent Pool amid US launch.
  3. GSK - ViiV Healthcare Meet the Management.
  4. GENE ONLINE - GSK Boosts HIV Drug Business Forecasts as Apretude Sales Surge.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.